Prediction of clinical outcome in non-small cell lung cancer (NSCLC) patients treated with gefitinib using Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) of serum.
暂无分享,去创建一个
F. Hirsch | D. Carbone | P. Bunn | B. Solomon | M. Duncan | H. Roder | K. Kasahara | V. Gregorc | F. Taguchi | M. Nishio